Shanghai RAAS Blood Products Co., Ltd. (SHE: 002252)

Market Cap	45.97B
Revenue (ttm)	8.32B
Net Income (ttm)	1.78B
Shares Out	6.60B
EPS (ttm)	0.27
PE Ratio	25.96
Forward PE	19.89
Dividend	0.03 (0.43%)
Ex-Dividend Date	Jun 5, 2024

Volume	18,431,700
Open	7.05
Previous Close	6.96
Day's Range	6.87 - 7.05
52-Week Range	5.93 - 8.68
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Shanghai RAAS Blood Products

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 3,254
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2023, Shanghai RAAS Blood Products's revenue was 7.96 billion, an increase of 21.27% compared to the previous year's 6.57 billion. Earnings were 1.78 billion, a decrease of -5.35%.